Drug intelligence / Profile preview

4A10

Development stage: Phase 1
Lead developer: Allterum Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

4A10 is a monoclonal antibody developed by Allterum Therapeutics, licensed from the National Cancer Institute (NCI). It targets the CD127 receptor, also known as the Interleukin-7 receptor alpha chain, and is being developed for the treatment of various cancers, with a primary focus on hematological malignancies such as acute lymphoblastic leukemia (ALL) and pediatric T-cell acute lymphoblastic leukemia (T-ALL). The drug has received FDA orphan drug and rare pediatric disease designations.

Other names: anti-IL-7Rα 4A10anti-IL-7Rα (4A10)

Targets

IL7R (Interleukin-7 Receptor)

Beyond the preview

Go deeper on 4A10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4A10.

Explore the full profile